SHARON, Pa., June 22 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC Pink Sheets: NNLX), a nanobiotechnology company engaged in the development and commercialization of technologies for the creation of hydrogen utilizing hydrogen bioreactors, announced today that it has signed an agreement for the construction and operation of a prototype hydrogen bioreactor at the City of Erie wastewater treatment plant. This project will utilize the proprietary intellectual property of NanoLogix in conjunction with the participation of faculty members and students from Gannon University. Mitchell S. Felder, M.D., CEO of NanoLogix, Inc., stated that, "We are very enthusiastic about exploring the enormous potential for converting wastewater into hydrogen. The Erie Wastewater Treatment Plant treats between 30-40 million gallons per day from the sewer system. There are thousands of plants throughout America. Success in this arena could greatly alleviate American dependence upon foreign energy sources." Joe Sinnott, Esq., the Mayor of Erie, added, "We are proud to have the City of Erie in the forefront of the technological fight for American energy independence. Our collective success could permanently change the worldwide energy paradigm."
About NanoLogix, Inc.
NanoLogix is a nano-biotechnology company whose extensive portfolio of patents have application and marketability in the following areas: nanoscale microfluidics for the rapid identification of disease causing pathogens utilizing BioMEMS; production of high value hydrogen from agricultural feedstock, industrial waste water and municipal waste streams; nontoxic induction of apoptosis (a method for inducing a genetically based induction of "cell suicide") in cancer cells utilizing hydrophobic hydrocarbons; and the bio-remediation of air, water and soils of harmful contaminants.
Forward-Looking Statements
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
FOR FURTHER INFORMATION, go to the Company's website at: http://www.nanologix/.
